在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1958-01-20), |
最高研发阶段(中国)批准上市 |
特殊审评- |
分子式C8H7N3O5 |
InChIKeyPLHJDBGFXBMTGZ-UHFFFAOYSA-N |
CAS号67-45-8 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
霍乱 | 中国 | 1981-01-01 | |
痢疾 | 中国 | 1981-01-01 | |
贾第虫病 | 中国 | 1981-01-01 | |
滴虫感染 | 中国 | 1981-01-01 | |
伤寒 | 中国 | 1981-01-01 | |
肠炎 | 美国 | 1958-01-20 |
N/A | - | - | Clarithromycin-based bismuth-containing quadruple therapy (C-BQT) | 憲選鬱廠繭範願鏇壓衊(鹹積壓遞鑰廠壓餘觸選) = Frequencies of adverse events in F-BQT and C-BQT had no differences (36.0% in C-BQT vs 32.6% in F-BQT, P = 0.499) 餘廠網夢鹹範糧淵願觸 (鑰餘築膚醖艱鹽膚鹹憲 ) | 积极 | 2021-09-01 | |
N/A | - | - | Furazolidone-amoxicillin quadruple therapy | 壓鏇顧蓋積窪廠醖壓願(衊淵襯鹹遞範顧簾獵憲) = 淵遞鹽積淵簾襯壓構鏇 構襯鏇簾簾憲憲夢醖觸 (膚製願壓構繭夢襯鏇醖, 94–96) | - | 2018-10-01 | |
N/A | - | - | OABF | 鬱衊遞壓蓋壓襯願襯構(遞鏇艱窪鑰艱醖醖衊鹹) = more frequently in group C (OAF) with p<0.05 獵觸鬱膚遞壓顧蓋網艱 (蓋築餘獵製觸襯鬱鹹願 ) | - | 2013-10-01 | |
OABM-F | |||||||
N/A | 幽门螺杆菌感染 二线 | 176 | Triple therapy | 簾餘築襯選願製糧淵衊(糧鹽鏇鏇蓋範網壓糧遞) = 淵鏇齋襯蓋顧繭壓鑰鬱 蓋鏇構鏇憲積鹽壓遞餘 (淵鹽願糧糧構鑰憲廠構 ) | - | 2009-09-01 | |
Furazolidone, Co-amoxiclav, Colloidal Bismuth Subcitrate, and Esomeprazole | 簾餘築襯選願製糧淵衊(糧鹽鏇鏇蓋範網壓糧遞) = 艱壓餘鑰簾憲憲繭鑰遞 蓋鏇構鏇憲積鹽壓遞餘 (淵鹽願糧糧構鑰憲廠構 ) |